MedTrace Logo

Postoperative Respiratory Complications According to Neuromuscular Block Reversal After MICS

NCT04957836 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1216

Last updated 2024-08-12

No results posted yet for this study

Summary

Postoperative respiratory complications according to the type of drug (sugammadex, pyridostigmine) used for reversible neuromuscular block when extubating an endotracheal tube in the operating room after minimally invasive cardiac surgery, and the length of intensive care unit stay are going to be checked. Through these results, it will be investigated whether the use of rocuronium-sugarmadex for neuromuscular block and reversal in patients undergoing minimally invasive cardiac surgery is clinically useful.

Conditions

  • Minimally Invasive Cardiac Surgery

Interventions

OTHER

reversal with sugammadex

reversal with sugammadex for immediate extubation in the operating room

Sponsors & Collaborators

  • Pusan National University Yangsan Hospital

    lead OTHER

Principal Investigators

  • Hee Young Kim, MD, PhD · Pusan National University Yangsan Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-21
Primary Completion
2021-06-29
Completion
2021-06-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04957836 on ClinicalTrials.gov